BofA has initiated coverage of Candel Therapeutics (NASDAQ:CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110. "While approved therapies may ...

Fintel reports that on February 7, 2025, B of A Securities initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy recommendation. As of January 29, 2025, the average one-year price ...

Shares of Candel Therapeutics surged after its board chair picked up 1.25 million shares of the company. The stock gained 44% at $9.39 on Thursday. Shares are up over 760% for the past year.

The Bengaluru man shared a receipt from the fruit shop showing pomegranate labelled as "anaar".(X/sgowda) Surprised by the use of the word 'anaar' for pomegranate, the user took to social media to ...

Bullish option flow detected in Candel Therapeutics (CADL) Inc with 3,986 calls trading, 3x expected, and implied vol increasing almost 24 points to 171.94%. Dec-24 7 calls and Jan-25 4 puts are ...